Transition Bio

About:

Transition Bio provides condensate technology for drug discovery and diagnostics.

Website: https://www.transitionbio.com/

Top Investors: Bristol-Myers Squibb, Northpond Ventures, Taiho Ventures, Lifeforce Capital, Magnetic Ventures

Description:

Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.

Total Funding Amount:

$63.3M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2020-01-01

Founders:

David Weitz, Peter St George-Hyslop, Sarah Teichmann, Tuomas Knowles

Number of Employees:

11-50

Last Funding Date:

2024-10-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai